# BPC-157 TB-500: The Wolverine Two-Peptide Repair Blend, On the Record > BPC-157 TB-500 is the Wolverine blend — BPC-157 paired with TB-500. The tendon, wound, and angiogenesis research, the dose ranges, and the FDA 503A access record, set in glazed tiles and cited. Two peptides, one panel: BPC-157 supplies the cytoprotective, pro-angiogenic signal; TB-500 supplies the cell-migration signal. Every finding is single-compound, mostly rodent, and cited to its study. ## What the Wolverine blend sets side by side BPC-157 TB-500 is the research-community name for a two-peptide tissue-repair pairing marketed as "Wolverine." It is not a single chemical entity and not an approved product. It pairs BPC-157 — Body Protection Compound 157, a synthetic 15-amino-acid pentadecapeptide (sequence GEPPPGKPADDAGLV, ~1419 Da) derived from a human gastric-juice protein — with TB-500, the synthetic N-acetylated heptapeptide Ac-LKKTETQ (~889 Da) corresponding to residues 17-23 of Thymosin Beta-4 [1][3]. The two peptides do different jobs. BPC-157 acts as a local cytoprotective and pro-angiogenic signal: it up-regulates VEGFR2 with downstream Akt-eNOS activation and accelerated blood-flow recovery in ischemic rat muscle [2]. TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization [3]. The blend's appeal is that these are complementary, largely non-overlapping pathways. The honest caveat sits right beside it: no controlled study has tested the two together, and a 2025 systematic review of BPC-157 in orthopaedic sports medicine — 36 studies, only one in humans — found "no clinical safety data" and makes no mention of TB-500 or any combination [9]. This site is a reading panel, not a clinic and not a vendor. It sets each finding and each constituent in its own tile, marks which leg of the blend an evidence point belongs to, and lays the [Wolverine legal status and 503A access](/legal-status) record out in the open rather than burying it. ## BPC 157 TB 500: What the Wolverine Blend Pairs BPC 157 TB 500 — the unpunctuated form of the same pairing — pairs two peptides with two distinct, independently characterized mechanisms. BPC-157 is the cytoprotective, pro-angiogenic leg; TB-500 is the cytoskeletal, cell-migration leg. The pairing is read as "two complementary modules, one repair panel," which is the rationale behind the "synergy" claim. That synergy is a theoretical extrapolation, not a measured result. No peer-reviewed study defines a synergy ratio, dose, or endpoint for the two given together. The structural and signaling facts for each peptide are well attested individually [2][3]; the combined effect is an inference from those separate mechanisms. The [BPC-157 and TB-500 mechanisms](/research) page sets the two legs out in full, side by side. ## What the BPC-157 TB-500 Stack Is The BPC-157 TB-500 stack is a two-peptide tissue-repair pairing, not an approved medicine. Commercial "Wolverine" vials are commonly labeled with a combined per-vial mass — for example ~10 mg BPC-157 + ~10 mg TB-500 — but no standardized composition or ratio is clinically validated, and the actual BPC-157:TB-500 ratio in unregulated material is not guaranteed [1]. A second identity caveat compounds the first. "TB-500" as sold is the Ac-LKKTETQ heptapeptide (~889 Da), but the overwhelming majority of efficacy data attributed to it were generated with full-length Thymosin Beta-4 (~4963 Da) [4][8]. The blend inherits that gap for one of its two components. Read the [research dose ranges](/dosage) and the honest limits before treating any vendor protocol as validated. ## What the record contains, and what it does not Read plainly, the BPC-157 TB-500 evidence sorts into two stacks. The first is genuinely strong, and it is single-compound and preclinical: BPC-157 restored load-to-failure in fully transected rat Achilles tendon at 10 microg/kg [1] and improved blood-flow recovery in ischemic rat muscle through a VEGFR2-Akt-eNOS angiogenic signal [2]; Thymosin Beta-4 raised re-epithelialization 42% at 4 days and up to 61% at 7 days in a rat wound model [5] and has a 2-angstrom crystal structure for its 1:1 G-actin sequestration [3]. Those are not marketing claims. They are measured results with citations. The second stack is what is missing, and it is the part a "legit" reading has to keep in view. There is no controlled trial of the combination, no defined synergy ratio or endpoint, and a 2025 systematic review of BPC-157 — 36 studies, one human — recorded "no clinical safety data" and did not mention TB-500 [9]. Human data exist only for the individual peptides and are thin, and the human "TB-500" data are actually for the full-length parent protein [4][8]. This site keeps both stacks visible: the [BPC-157 and TB-500 mechanisms](/research) and the [BPC-157 TB-500 wound healing research](/wound-healing-research) on one side, the gaps and the [Wolverine legal status and 503A access](/legal-status) record on the other. --- A glazed-tile reading panel on the BPC-157 TB-500 blend — each tendon, wound, and angiogenesis study set in its own tile beside the FDA 503A and access record, with no clinic behind the panel and nothing here dispensed.